| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers X > Headlines for XenoPort, Inc. > News item |
XenoPort to develop XP21279 for Parkinson's disease, divert resources from migraine treatment
New York, Nov. 2 - XenoPort, Inc. said it has selected XP21279 as a development compound for treatment of Parkinson's disease.
XP21279 is a transported prodrug of levodopa (L-Dopa), which is still the most effective treatment for the disease, especially for patients with severe cases, the company said.
Because it is designed to use natural nutrient transport mechanisms through the gastrointestinal tract and then to be rapidly converted into L-Dopa, XP21279 has the potential to be formulated for sustained release, XenoPort said.
Current L-Dopa therapy is "suboptimal" due to fluctuations in L-Dopa blood concentrations between doses, the company noted.
XenoPort plans to file an investigational new drug application for XP21279 with the U.S. Food and Drug Administration in the first half of 2007.
In order to focus resources on the drug, the company is postponing its previously planned filing of an investigational new drug application for XP20295, a transported prodrug of propofol for the treatment of nausea and vomiting due to migraines and chemotherapy, "until additional resources become available."
"We remain excited about the potential of XP20925 and plan to continue its development at an appropriate time in the future," said Ronald Barrett, XenoPort's chief executive officer, in a news release.
"We have decided to prioritize the development of XP21279 because of the established market potential for an improved L-Dopa product in Parkinson's disease and the possibility of demonstrating the desired product profile in early clinical studies."
XenoPort is a Santa Clara, Calif., biopharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.